Nuveen LLC Takes Position in Spyre Therapeutics, Inc. $SYRE

Key Points

• Nuveen LLC made a new investment in Spyre Therapeutics, acquiring 140,129 shares valued at approximately $2.26 million, representing 0.23% of the company as of their latest SEC filing.
• Spyre Therapeutics has received positive analyst attention, with a consensus rating of "Buy" and a price target of $53.40, driven by a recent earnings report that beat expectations.
• As of now, shares of Spyre Therapeutics are trading around $16.49, having experienced a decline of 1.4%, and the company has a market cap of $996 million.

Nuveen LLC acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 140,129 shares of the company's stock, valued at approximately $2,261,000. Nuveen LLC owned 0.23% of Spyre Therapeutics as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the stock. Driehaus Capital Management LLC lifted its stake in Spyre Therapeutics by 308.1% in the fourth quarter. Driehaus Capital Management LLC now owns 2,803,655 shares of the company's stock valued at $65,269,000 after acquiring an additional 2,116,575 shares during the last quarter. Jefferies Financial Group Inc. lifted its holdings in shares of Spyre Therapeutics by 167.6% during the fourth quarter. Jefferies Financial Group Inc. now owns 1,216,954 shares of the company's stock worth $28,331,000 after buying an additional 762,147 shares during the last quarter. Boxer Capital Management LLC acquired a new position in shares of Spyre Therapeutics during the fourth quarter worth approximately $10,864,000. Deerfield Management Company L.P. Series C acquired a new stake in shares of Spyre Therapeutics during the 4th quarter worth approximately $10,476,000. Finally, Braidwell LP grew its holdings in shares of Spyre Therapeutics by 17.7% during the 4th quarter. Braidwell LP now owns 2,578,404 shares of the company's stock worth $60,025,000 after purchasing an additional 388,568 shares in the last quarter. Institutional investors and hedge funds own 80.39% of the company's stock.

Spyre Therapeutics Price Performance

NASDAQ:SYRE traded down $0.23 during trading hours on Monday, reaching $16.49. 351,933 shares of the stock were exchanged, compared to its average volume of 456,133. The stock has a market cap of $996.00 million, a PE ratio of -4.85 and a beta of 2.87. Spyre Therapeutics, Inc. has a twelve month low of $10.91 and a twelve month high of $40.26. The firm has a 50 day moving average of $16.33 and a 200 day moving average of $16.22.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.24. Equities research analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Wall Street Zen cut Spyre Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday. Wedbush reissued an "outperform" rating and issued a $65.00 price target on shares of Spyre Therapeutics in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the company. According to MarketBeat.com, Spyre Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $53.40.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).